ABEV vs DEO

ABEV's deterministic health score is weak with a Piotroski F-Score of 4/9, indicating marginal financial stability. The stock trades above the Graham Number of $2.24 at a current price of $2.78, suggesting modest overvaluation for a defensive stock, though below the growth-based intrinsic value of $5.9. Strong profitability metrics like a 17.73% profit margin and 26.01% operating margin are offset by declining revenue growth of -5.70% YoY and a concerning 104.3% dividend payout ratio. Analysts rate it a 'hold' with a $2.93 target, implying limited upside.

Despite a strong Piotroski F-Score of 7/9 indicating operational stability, DEO is exhibiting severe fundamental decay and technical weakness. The stock is trading at a significant premium to both its Graham Number ($10.62) and Intrinsic Value ($49.15), while facing a catastrophic collapse in earnings growth (-62.3% YoY EPS). A dividend payout ratio of 95.64% is unsustainable given the negative revenue growth and crashing quarterly EPS, suggesting a high risk of a dividend cut. The technical trend is completely bearish (0/100), and long-term price performance is dismal (-49.1% over 5 years).